Noninvasive biomarkers of liver status, such as PRO-C3 for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), which specifically target the dynamics of liver fibrosis, provide a novel tool to determine a patient's disease progression.

Such liver disease biomarkers could be used for risk stratification of patients as well as prognostic enrichment of clinical trials targeting the neediest and highest risk patients, thereby increasing the likelihood of success.

 

 

Watch the entire webinar series on our YouTube Channel!

Please don't hesitate to contact us if you have any questions or other inquiries.

Please don't hesitate to contact us if you have any questions or other inquiries.

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.